Author Title [ Type(Desc)] Year
Filters: Author is Banz, Yara  [Clear All Filters]
Journal Article
Leimkühler NB, Gleitz HFE, Ronghui L, Snoeren IAM, Fuchs SNR, Nagai JS, Banjanin B, Lam KH, Vogl T, Kuppe C, et al. Heterogeneous bone-marrow stromal progenitors drive myelofibrosis via a druggable alarmin axis. Cell Stem Cell. 2020.
Mager LF, Riether C, Schürch CM, Banz Y, Wasmer M-H, Stuber R, Theocharides AP, Li X, Xia Y, Saito H, et al. IL-33 signaling contributes to the pathogenesis of myeloproliferative neoplasms. J Clin Invest. 2015.
Dzhonova D, Olariu R, Leckenby J, Dhayani A, Vemula PKumar, Prost J-C, Banz Y, Taddeo A, Rieben R. Local release of tacrolimus from hydrogel-based drug delivery system is controlled by inflammatory enzymes in vivo and can be monitored non-invasively using in vivo imaging. PLoS One. 2018;13(8):e0203409.
Betticher C, Bacher U, Legros M, Zimmerli S, Banz Y, Taleghani BMansouri, Pabst T. Prophylactic corticosteroid use prevents engraftment syndrome in patients after autologous stem cell transplantation. Hematol Oncol. 2020.
Gajanayake T, Olariu R, Leclère FM, Dhayani A, Yang Z, Bongoni AK, Banz Y, Constantinescu MA, Karp JM, Vemula PKumar, et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. Sci Transl Med. 2014;6(249):249ra110.
Berger MD, Branger G, Klaeser B, Taleghani BMansouri, Novak U, Banz Y, Mueller BU, Pabst T. Zevalin and BEAM (Z-BEAM) versus rituximab and BEAM (R-BEAM) conditioning chemotherapy prior to autologous stem cell transplantation in patients with mantle cell lymphoma. Hematol Oncol. 2015.